Literature DB >> 15095090

BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas.

Paula Soares1, Vítor Trovisco, Ana Sofia Rocha, Tália Feijão, Ana Paula Rebocho, Elsa Fonseca, Inês Vieira de Castro, José Cameselle-Teijeiro, Manuel Cardoso-Oliveira, Manuel Sobrinho-Simões.   

Abstract

Somatic mutations of the BRAF gene (BRAFV599E and BRAFK600E) were found to be closely associated with different histotypes of papillary thyroid carcinoma (PTC). The V599E mutation is highly prevalent in PTC with a papillary or mixed papillary follicular growth pattern, and the K600E mutation is apparently restricted to the follicular variant of PTC. It is usually accepted that thyroid malignancies may follow a progression path from well-differentiated to poorly differentiated (PDC) and undifferentiated (UC) carcinomas. One would expect that at least some of the less differentiated carcinomas would harbour the genetic alterations of pre-existing well-differentiated tumours. In order to find the prevalence of BRAF mutations in PDC and UC, we screened a series of 19 PDCs and 17 UCs, as well as 3 UC-derived cell lines, for both mutation types. The group of PDCs was restricted to the so-called insular and insular-like PDCs, thus excluding PTCs with solid, insular or trabecular foci of growth and PDCs displaying typical PTC nuclei. No BRAF mutations were detected in any of the 19 cases of PDC, whereas 6 of the UCs (35%) and one UC-derived cell line presented the BRAFV599E mutation. The BRAFK600E mutation was not detected in any case. We conclude that UC may progress from BRAFV599E-mutated PTC. The absence of BRAF mutations in our series of PDC supports the assumption that pure insular and insular-like PDCs are more closely related to follicular carcinoma than to PTC. Copyright 2004 Springer-Verlag

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095090     DOI: 10.1007/s00428-004-1018-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  24 in total

1.  Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis.

Authors:  G Garcia-Rostan; R L Camp; A Herrero; M L Carcangiu; D L Rimm; G Tallini
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

2.  RET activation and clinicopathologic features in poorly differentiated thyroid tumors.

Authors:  Massimo Santoro; Mauro Papotti; Gennaro Chiappetta; Ginesa Garcia-Rostan; Marco Volante; Chaline Johnson; Robert L Camp; Francesca Pentimalli; Carmen Monaco; Agustin Herrero; Maria Luisa Carcangiu; Alfredo Fusco; Giovanni Tallini
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

3.  Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR.

Authors:  O M Sheils; J J O'Leary; E C Sweeney
Journal:  J Pathol       Date:  2000-09       Impact factor: 7.996

4.  Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Authors:  M Santoro; F Carlomagno; I D Hay; M A Herrmann; M Grieco; R Melillo; M A Pierotti; I Bongarzone; G Della Porta; N Berger
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

5.  RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.

Authors:  G Tallini; M Santoro; M Helie; F Carlomagno; G Salvatore; G Chiappetta; M L Carcangiu; A Fusco
Journal:  Clin Cancer Res       Date:  1998-02       Impact factor: 12.531

6.  Papillary and follicular thyroid carcinomas with an insular component.

Authors:  R Ashfaq; F Vuitch; R Delgado; J Albores-Saavedra
Journal:  Cancer       Date:  1994-01-15       Impact factor: 6.860

7.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

Authors:  Marina N Nikiforova; Roy A Lynch; Paul W Biddinger; Erik K Alexander; Gerald W Dorn; Giovanni Tallini; Todd G Kroll; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

8.  BRAF mutations in papillary carcinomas of the thyroid.

Authors:  Toshihiko Fukushima; Shinichi Suzuki; Miyuki Mashiko; Tohru Ohtake; Yoshiyuki Endo; Yuji Takebayashi; Koji Sekikawa; Koichi Hagiwara; Seiichi Takenoshita
Journal:  Oncogene       Date:  2003-09-25       Impact factor: 9.867

9.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.

Authors:  Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Jorge Lima; Patrícia Castro; Ana Preto; Valdemar Máximo; Tiago Botelho; Raquel Seruca; Manuel Sobrinho-Simões
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

10.  E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas.

Authors:  A S Rocha; P Soares; E Fonseca; J Cameselle-Teijeiro; M C Oliveira; M Sobrinho-Simões
Journal:  Histopathology       Date:  2003-06       Impact factor: 5.087

View more
  28 in total

Review 1.  Diagnostic criteria in well-differentiated thyroid carcinomas.

Authors:  Elsa Fonseca; Paula Soares; Manuel Cardoso-Oliveira; Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

Review 2.  An evidence-based review of poorly differentiated thyroid cancer.

Authors:  Enoch M Sanders; Virginia A LiVolsi; James Brierley; Jennifer Shin; Gregory W Randolph
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 3.  Alterations of the BRAF gene in thyroid tumors.

Authors:  Raffaele Ciampi; Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

4.  Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers.

Authors:  Luke K Genutis; Jerneja Tomsic; Ralf A Bundschuh; Pamela L Brock; Michelle D Williams; Sameek Roychowdhury; Julie W Reeser; Wendy L Frankel; Mohammed Alsomali; Mark J Routbort; Russell R Broaddus; Paul E Wakely; John E Phay; Christopher J Walker; Albert de la Chapelle
Journal:  Thyroid       Date:  2019-03-27       Impact factor: 6.568

Review 5.  Molecular pathology of well-differentiated thyroid carcinomas.

Authors:  Manuel Sobrinho-Simões; Ana Preto; Ana Sofia Rocha; Patrícia Castro; Valdemar Máximo; Elsa Fonseca; Paula Soares
Journal:  Virchows Arch       Date:  2005-09-28       Impact factor: 4.064

6.  Thyroglossal duct cyst cancer most likely arises from a thyroid gland remnant.

Authors:  Esther D Rossi; Maurizio Martini; Patrizia Straccia; Alessandra Cocomazzi; Ilaria Pennacchia; Luca Revelli; Armando Rossi; Celestino Pio Lombardi; Luigi M Larocca; Guido Fadda
Journal:  Virchows Arch       Date:  2014-04-29       Impact factor: 4.064

7.  Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours.

Authors:  Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

Review 8.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

Review 9.  Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).

Authors:  Carmelo Nucera; Melanie Goldfarb; Richard Hodin; Sareh Parangi
Journal:  Biochim Biophys Acta       Date:  2009-01-31

10.  Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.

Authors:  Ana Preto; Joana Gonçalves; Ana P Rebocho; Joana Figueiredo; Ana M Meireles; Ana S Rocha; Helena M Vasconcelos; Hugo Seca; Raquel Seruca; Paula Soares; Manuel Sobrinho-Simões
Journal:  BMC Cancer       Date:  2009-10-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.